{filename}

Publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Biofluid Biology of neoplasia Biomarker Analysis Biomarker Validation Biomarkers Bladder Brain Breast Cancer CDKN2A mutation Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparison study Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Profiling Gene Fusions Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-related Colitis Immuno-Oncology Immunotherapy Inflammation Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR pathway Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis PBMCs PCA Cell Lines PIK3CA mutation Placenta Plasma Platform Comparison Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate qNPA qPCR Radioimmunotherapy Rearrangements Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Carcinoma SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid Therapeutic Response Therapeutic targets TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Urothelial carcinoma VEGFR Xenograft Tissue

Integrated Molecular Profiling of Genitourinary Tumors: Applications for Personalized Radiotherapy

 

Webcast abstract:

Advances in therapeutic radiation delivery coupled with improved systemic therapy, including targeted agents and immunotherapy, are revolutionizing the oncology landscape.  Emerging multi-modality treatments have increased control rates for virtually all cancers and in some cases have rendered durable remissions for patients with advanced and metastatic disease.  This revolution has emerged in large part from comprehensive tumor molecular profiling efforts and has led to the development of novel minimally invasive biomarkers -- an essential tool in guiding future personalized therapy.

In this webcast, we will review the recent history of molecular profiling in genitourinary cancers and discuss the utility of novel minimally invasive biomarkers in both patient selection and treatment delivery. We will focus on prostate and bladder cancer and review recent advances, strategies for improved delivery of radiotherapy in the era of personalized oncology, and ongoing challenges and opportunities.

Speaker

Omar Y. Mian MD, Phd, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Associate Staff Physician, Dept of Radiation Oncology, Department of Translational Hematology and Oncology Rsearch, Cleveland Clinic Foundation, Cleveland, OH

Speaker Biography

Dr. Mian is a Radiation Oncologist and Physician Scientist in the Department of Translational Hematology and Oncology Research (THOR) at the Cleveland Clinic. His clinical specialty is genitourinary tract cancers (bladder, prostate, kidney). His laboratory investigates mechanisms of epigenetic dysregulation in prostate and bladder cancer and is developing novel circulating biomarkers using integrated genomics.

Return To List